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More than 25% of the U.S. popula-tion aged $65 years has diabetes(1), and the aging of the overall
population is a signiﬁcant driver of the
diabetes epidemic. Although the burden
of diabetes is often described in terms of
its impact on working-age adults, diabetes
in older adults is linked to highermortality,
reduced functional status, and increased
risk of institutionalization (2). Older adults
with diabetes are at substantial risk for both
acute and chronic microvascular and car-
diovascular complications of the disease.
Despite having thehighest prevalence of
diabetes of any age-group, older persons
and/or those with multiple comorbidities
have often been excluded from randomized
controlled trials of treatmentsdand treat-
ment targetsdfor diabetes and its associated
conditions. Heterogeneity of health status of
older adults (even within an age range) and
the dearth of evidence from clinical trials
present challenges to determining standard
intervention strategies that ﬁt all older
adults. To address these issues, the Ameri-
can Diabetes Association (ADA) convened
a Consensus Development Conference on
Diabetes and Older Adults (deﬁned as
those aged $65 years) in February
2012. Following a series of scientiﬁc pre-
sentations by experts in the ﬁeld, the
writing group independently developed
this consensus report to address the fol-
lowing questions:
1. What is the epidemiology and patho-
genesis of diabetes in older adults?
2. What is the evidence for preventing
and treating diabetes and its common
comorbidities in older adults?
3. What current guidelines exist for
treating diabetes in older adults?
4. What issues need to be considered in
individualizing treatment recommen-
dations for older adults?
5. What are consensus recommendations
for treating older adults with or at risk
for diabetes?
6. How can gaps in the evidence best be
ﬁlled?
What is the epidemiology
and pathogenesis of diabetes
in older adults?dAccording to the
most recent surveillance data, the preva-
lence of diabetes among U.S. adults aged
$65 years varies from 22 to 33%, depend-
ing on the diagnostic criteria used. Post-
prandial hyperglycemia is a prominent
characteristic of type 2 diabetes in older
adults (3,4), contributing to observed dif-
ferences in prevalence depending onwhich
diagnostic test is used (5). Using the A1C or
fasting plasma glucose (FPG) diagnostic
criteria, as is currently done for national
surveillance, one-third of older adults
with diabetes are undiagnosed (1).
The epidemicof type2diabetes is clearly
linked to increasing rates of overweight and
obesity in the U.S. population, but pro-
jections by the Centers for Disease Control
and Prevention (CDC) suggest that even
if diabetes incidence rates level off, the
prevalence of diabetes will double in the
next 20 years, in part due to the aging of
the population (6). Other projections sug-
gest that the number of cases of diagnosed
diabetes in those aged $65 years will in-
crease by 4.5-fold (compared to 3-fold in
the total population) between 2005 and
2050 (7).
The incidence of diabetes increaseswith
age until about age 65 years, after which
both incidence and prevalence seem to level
off (www.cdc.gov/diabetes/statistics). As a
result, older adults with diabetes may either
have incident disease (diagnosed after age
65 years) or long-standing diabeteswith on-
set in middle age or earlier. Demographic
and clinical characteristics of these two
groups differ in a number of ways, adding
to the complexity of making generalized
treatment recommendations for older pa-
tients with diabetes. Older-age–onset dia-
betes is more common in non-Hispanic
whites and is characterized by lower
mean A1C and lower likelihood of insulin
use than is middle-age–onset diabetes.
Although a history of retinopathy is signif-
icantly more common in older adults with
middle-age–onset diabetes than those with
older-age onset, there is, interestingly, no
difference in prevalence of cardiovascular
disease (CVD) or peripheral neuropathy
by age of onset (8).
Older adults with diabetes have the
highest rates of major lower-extremity am-
putation (9), myocardial infarction (MI),
visual impairment, and end-stage renal dis-
ease of any age-group. Those aged $75
years have higher rates than those aged
65–74 years for most complications.
Deaths from hyperglycemic crises also are
signiﬁcantly higher in older adults (al-
though rates have declined markedly in
the past 2 decades). Those aged$75 years
also have double the rate of emergency de-
partment visits for hypoglycemia than the
general population with diabetes (10).
Although increasing numbers of indi-
viduals with type 1 diabetes are living into
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old age (11), this discussion of pathophy-
siology concerns type 2 diabetesd
overwhelmingly the most common incident
and prevalent type in older age-groups.
Older adults are at high risk for the develop-
ment of type 2 diabetes due to the combined
effects of increasing insulin resistance and
impaired pancreatic islet function with ag-
ing. Age-related insulin resistance appears to
be primarily associated with adiposity,
sarcopenia, and physical inactivity (12),
which may partially explain the dispropor-
tionate success of the intensive lifestyle in-
tervention in older participants in the
Diabetes Prevention Program (DPP) (13).
However, age-related declines of pancreatic
islet function (4,14) and islet proliferative
capacity (15,16) have previously been
described.
What is the evidence for
preventing and treating
diabetes and its common
comorbidities in older adults?
Screening for diabetes and
prediabetes
Older adults are at high risk for both
diabetes and prediabetes, with surveillance
data suggesting that half of older adults
have the latter (1). The ADA recommends
that overweight adults with risk factorsd
and all adults aged $45 yearsdbe
screened in the clinical setting every 1–3
years using either an FPG test, A1C, or
oral glucose tolerance test. The recommen-
dations are based on substantial indirect
evidence for the beneﬁts of early treatment
of type 2 diabetes, the fact that type 2 di-
abetes is typically present for years before
clinical diagnosis, and the evidence that
signs of complications are prevalent in
“newly diagnosed” patients (17).
The beneﬁts of identiﬁcation of pre-
diabetes and asymptomatic type 2 diabe-
tes in older adults depend on whether
primary or secondary preventive inter-
ventions would likely be effective and on
the anticipated timeframe of the beneﬁt of
interventions versus the patient’s life ex-
pectancy. Most would agree that a func-
tional and generally healthy 66-year-old
individual should be offered diabetes
screening since interventions to prevent
type 2 diabetes or the complications of
type 2 diabetes would likely be beneﬁcial
given the presumption of decades of re-
maining life. Most would also agree that
ﬁnding prediabetes or early type 2 diabe-
tes in a 95-year-old individual with ad-
vanced dementia would be unlikely to
provide beneﬁt.
Prevention or delay of type 2
diabetes
Numerous clinical trials have shown that
in high-risk subjects (particularly those
with impaired glucose tolerance), type 2
diabetes can be prevented or delayed by
lifestyle interventions or by various classes
of medications. These trials primarily
enrolled middle-aged participants. In the
DPP, which is the largest trial to date,
;20% of participants were aged $60
years at enrollment. These participants
seemed to have more efﬁcacy from the
lifestyle intervention than younger partic-
ipants, but did not appear to beneﬁt from
metformin (13,18). Follow-up of the DPP
cohort for 10 years after randomization
showed ongoing greater impact of the
original lifestyle intervention in older par-
ticipants (49% risk reduction in those
aged $60 years at randomization vs.
34% for the total cohort) (19) and addi-
tional beneﬁts of the lifestyle intervention
that might impact older adults, such as
reduction in urinary incontinence (20),
improvement in several quality-of-life do-
mains (21), and improvements in cardio-
vascular risk factors (22). Although these
results suggest that diabetes prevention
through lifestyle intervention be pursued
in relatively healthy older adults, the DPP
did not enroll signiﬁcant numbers over
the age of 70 years or those with func-
tional or cognitive impairments. Preven-
tive strategies that can be efﬁciently
implemented in clinical settings and in
the community have been developed
and evaluated (23), but as yet there has
been little focus on older adults in these
translational studies.
Interventions to treat diabetes
Glycemic control. A limited number of
randomized clinical trials in type 2 diabetes
form the basis of our current understanding
of the effects of glucose lowering on micro-
vascular complications, cardiovascular
complications, and mortality. While these
trials have provided invaluable data and
insights, theywere not designed to evaluate
the health effects of glucose control in
patients aged $75 years or in older adults
with poor health status. There are essen-
tially no directly applicable clinical trial
data on glucose control for large segments
of the older diabetic patient population.
The UK Prospective Diabetes Study
(UKPDS), which provided valuable evi-
dence of the beneﬁts of glycemic control
on microvascular complications, enrolled
middle-aged patients with newly diag-
nosed type 2 diabetes, excluding those
aged $65 years at the time of enrollment
(24,25). Microvascular beneﬁts persisted
during the post-trial follow-up period,
and statistically signiﬁcant reductions in
both mortality and MIs emerged, referred
to as the “legacy effect” of early glycemic
control (26).
After the publication of the main
UKPDS results, three major randomized
controlled trials (the Action to Control Car-
diovascular Risk in Diabetes [ACCORD]
trial, the Action in Diabetes and Vascular
Disease: Preterax and Diamicron MR Con-
trolled Evaluation [ADVANCE] trial, and
the Veterans Affairs Diabetes Trial [VADT])
were designed to speciﬁcally examine the
role of glycemic control in preventing CVD
events in middle-aged and older patients
with type 2 diabetes. The trials enrolled
patients at signiﬁcantly higher cardiovascu-
lar risk than did the UKPDS, with each
having a substantial proportion of partic-
ipants with a prior cardiovascular event,
mean age at enrollment in the 60s, and
established diabetes (8–11 years). Each of
these trials aimed, in the intensive glycemic
control arm, to reduce glucose levels to
near-normal levels (A1C,6.0 or,6.5%).
The glucose control portion of the
ACCORD trial was terminated after ap-
proximately 3 years because of excessive
deaths in the intensive glucose control arm
(27). The primary combined outcome of
MI, stroke, and cardiovascular death was
not signiﬁcantly reduced. Prespeciﬁed sub-
group analyses suggested that the dispro-
portionate cardiovascular mortality risk in
the intensive glycemic control groupwas in
participants under the age of 65 years as
opposed to older participants. However,
hypoglycemia and other adverse effects of
treatment were more common in older
participants (28).
The ADVANCE trial did not demon-
strate excessive deaths attributable to in-
tensive glucose control during a median
follow-up of 5 years. While there were no
statistically signiﬁcant cardiovascular ben-
eﬁts, there was a signiﬁcant reduction in
the incidence of nephropathy. In prespeci-
ﬁed subgroup analysis of age , or $65
years, there was no difference between
age-groups for the primary outcome (29).
Over 5 years of follow-up, the VADT
found no statistically signiﬁcant effect of
intensive glucose control on major cardio-
vascular events or death, but it did ﬁnd
signiﬁcant reductions in onset and pro-
gression of albuminuria (30). The trial did
not have prespeciﬁed subgroup analyses
by age. Post hoc analyses suggested that
mortality in the intensive versus standard
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glycemic control arm was related to dura-
tion of diabetes at the time of study enroll-
ment. Those with diabetes duration less
than 15 years had a mortality beneﬁt in
the intensive arm, while those with dura-
tion of 20 years or more had higher mor-
tality in the intensive arm (31).
These three trials add to the uncer-
tainty regarding the beneﬁts and risks of
more intensive treatment of hyperglycemia
in older adults. An ADA position statement
surmised that the combination of theUKPDS
follow-up study and subset analyses of the
later trials ‘‘. . . suggest the hypothesis that
patients with shorter duration of type 2 di-
abetes and without established atheroscle-
rosis might reap cardiovascular beneﬁt
from intensive glycemic control, [while]
. . . potential risks of intensive glycemic
control may outweigh its beneﬁts in other
patients, such as those with a very long du-
ration of diabetes, known history of severe
hypoglycemia, advanced atherosclerosis,
and advanced age/frailty” (32).
Recently, a Japanese trial reported
results of a multifactorial intervention ver-
sus standard care in about 1,000 patients
aged$65 years (mean age 72 years). After
6 years, no differences in mortality or car-
diovascular events were found, but the in-
tervention’s effect on glycemiawasminimal
and the number of events was low (33).
Since randomized controlled trials have
not included many older patients typical of
those in general practice, it is instructive to
observe the relationship between glycemic
control and complications in general pop-
ulations of older diabetic patients. A study
from the U.K. General Practice Research
Database showed that for type 2 diabetic
patients aged$50years (mean age64 years)
whose treatment was intensiﬁed from oral
monotherapy to addition of other oral
agents or insulin, there was a U-shaped as-
sociation between A1C and mortality, with
the lowest hazard ratio for death at an A1C
of about 7.5%. Low and high mean A1C
values were associated with increased all-
cause mortality and cardiac events (34). A
retrospective cohort study of 71,092 pa-
tients with type 2 diabetes aged $60 years
evaluated the relationships between baseline
A1C and subsequent outcomes (acute non-
fatal metabolic, microvascular, and cardio-
vascular events and mortality). As in the
prior study, mortality had a U-shaped rela-
tionship with A1C. Compared to risk with
A1C ,6.0%, mortality risk was lower
for A1C between 6.0 and 9.0% and higher
at A1C $11.0%. Risk of any end point
(complication or death) became signiﬁ-
cantly higher at A1C $8.0%. Patterns
were generally consistent across age-groups
(60–69, 70–79, and$80 years) (35).
Diabetes is associatedwith increased risk
of multiple coexisting medical conditions in
older adults ranging from CVD to cancer
and potentially impacting treatment deci-
sions, such as whether stringent glycemic
control would be of net beneﬁt (36,37). A
5-year longitudinal, observational study
of Italian patients with type 2 diabetes cat-
egorized patients into subgroups of high
(mean age 64.3 years [SD 9.5]) and low-
to-moderate comorbidity (mean age 61.7
years [SD 10.5]) using a validated patient-
reported measure of comorbidity. Having
an A1C of #6.5 or ,7% at baseline was
associated with lower 5-year incidence
of cardiovascular events in the low-to-
moderate comorbidity subgroup, but not
in the high comorbidity subgroup, sug-
gesting that patients with high levels of
comorbidity may not receive cardiovascu-
lar beneﬁt from intensive blood glucose
control (38).
Lipid lowering. There are no large trials
of lipid-lowering interventions speciﬁ-
cally in older adults with diabetes. Bene-
ﬁts have been extrapolated from trials of
older adults that include but are not
limited to those with diabetes and trials
of people with diabetes including but not
limited to older adults. A statin study in
older adults (participants aged 70–82
years) found a 15% reduction in coronary
artery disease events with pravastatin
(39,40). Ameta-analysis of 18,686 people
with diabetes in 14 trials of statin therapy
for primary prevention showed similar
20% relative reductions in major adverse
vascular outcomes in those under com-
pared with those over age 65 years (41).
Statin trials for secondary prevention of
CVD in adults with diabetes have also
demonstrated comparable relative reduc-
tions in recurrent cardiovascular events
and mortality by age-group (42). Since
older patients are at higher risk, absolute
risk reductions with statin therapy would
be greater in older patients. Cardiovascu-
lar prevention with statins, especially sec-
ondary beneﬁt, emerges fairly quickly
(within 1–2 years), suggesting that statins
may be indicated in nearly all older adults
with diabetes except those with very lim-
ited life expectancy.
The evidence for reduction in major
cardiovascular end points with drugs
other than statins is limited in any age-
group. The ACCORD lipid trial found no
beneﬁt of adding fenoﬁbrate to statin
therapy (43), and post hoc analyses sug-
gested that the negative results applied to
both those under and those over age 65
years (M.Miller, personal communication).
Subgroup analyses of the Fenoﬁbrate Inter-
vention and Event Lowering in Diabetes
(FIELD) study, which suggested some ben-
eﬁt of fenoﬁbrate in people with type 2 di-
abetes, suggested no beneﬁt in those aged
$65 years (44).
Blood pressure control. Multiple trials
have investigated the role of treatment of
hypertension to reduce the risk of cardio-
vascular events (17). Beneﬁt for older
adults with diabetes has been inferred
from the trials of older adults including
but not limited to those with diabetes and
from the trials of middle- and older-aged
adults with diabetes (42). There is consis-
tent evidence that lowering blood pres-
sure from very high levels (e.g., systolic
blood pressure [SBP] 170 mmHg) to
moderate targets (e.g., SBP 150 mmHg)
reduces cardiovascular risk in older
adults with diabetes. Selected trials have
shown beneﬁt with targets progressively
lower, down to SBP ,140 mmHg and di-
astolic blood pressure (DBP) ,80 mmHg
(45). The ACCORD-BP trial showed no
beneﬁt on the primary outcome (major
adverse cardiovascular events) of SBP tar-
gets ,120 mmHg compared with ,140
mmHg, but found a signiﬁcant reduction
in stroke, a secondary outcome (46). Sub-
group analyses of those aged, versus$65
years suggested that the stroke beneﬁt may
have been limited to the older cohort
(M. Miller, personal communication).
Observational analyses of other trial
cohorts suggest no beneﬁt to SBP targets
more aggressive than ,140 mmHg and
that lowDBPmay be a risk factor formor-
tality in older adults. A post hoc analysis
of the cohort of participants with diabe-
tes in the International Verapamil SR-
Trandolapril Study (INVEST), whose
mean age was ;65 years, showed that
achieved SBP under 130 mmHg was not
associated with improved cardiovascular
outcomes compared with SBP under 140
mmHg (47). This report validated SBP con-
trol under 140 mmHg, as death and cardio-
vascular events were more likely in subjects
whose SBPwas over 140mmHg. A post hoc
analysis of the VADT (in which the goal
blood pressure was,130/80 mmHg) simi-
larly showed that those whose SBP was
$140 mmHg had increased mortality,
while those at ,105 mmHg, 105–129
mmHg, and 130–139 mmHg had equally
low mortality rates. For DBP, achieved val-
ues,70mmHgwere associatedwithhigher
mortality, while those of 70–79 mmHg or
.80 mmHg were equally low (48).
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Aspirin. In populations without diabe-
tes, the greatest absolute beneﬁt of aspirin
therapy (75–162 mg) is for individuals
with a 10-year risk of coronary heart dis-
ease of 10% or greater (49). The increased
cardiovascular risk posed by diabetes and
aging and the known beneﬁts of aspirin
for secondary prevention suggest that, in
the absence of contraindications, this
therapy should be offered to virtually all
older adults with diabetes and known
CVD. However, the beneﬁts of aspirin
for primary prevention of CVD events
have not been thoroughly elucidated in
older adults with diabetes and must be
balanced against risk of adverse events
such as bleeding. A randomized study of
Japanese individuals with diabetes but no
CVD history demonstrated no signiﬁcant
beneﬁt of aspirin on the composite primary
outcome, but a subgroup analysis of sub-
jects aged $65 years demonstrated a sig-
niﬁcantly lower risk of the primary end
point with aspirin (50).
The incidence of gastrointestinal bleed-
ing with the use of aspirin has not been
directly compared in older- versus middle-
aged adults, but in separate studies the rates
were higher (1–10 per 1,000 annually) for
older adults (51) than those for middle-
aged adults (3 per 10,000 annually) (49).
More recently, the greater risk ofmajor gas-
trointestinal or intracerebral bleeding in
older adults who use aspirin was suggested
by an observational analysis, but diabetes
per se was not associated with increased
bleeding with aspirin (52). In light of the
probable higher risk of bleeding with age,
the beneﬁt of aspirin therapy in older adults
with diabetes is likely strongest for those
with high cardiovascular risk and low risk
of bleeding. Unfortunately, the risk factors
for these outcomes tend to overlap. When
aspirin is initiated, the use of agents such as
proton pump inhibitors to protect against
gastrointestinal bleeding may be warranted
(53). Further evidence is needed to con-
ﬁrm a clear role of aspirin for primary pre-
vention of cardiovascular events in older
adults with diabetes.
Screening for chronic diabetes
complications
The screening and interventions for chronic
diabetes complications recommended by
the ADA have a strong evidence base and
are cost-effective (54). However, as is the
case for many diabetes interventions, the
underlying evidence generally comes from
studies of younger adults. When consid-
ering chronic complications, the issues of
incident versus prevalent diabetes and
diabetes heterogeneity again need to be
raised. Some older adults have long-standing
diabetes with associated microvascular
and macrovascular complications. Others
have newly diagnosed diabetes with evi-
dence of complications (on screening
tests) at initial presentation, while still
others have newly diagnosed diabetes
without evidence of complications. For
relatively healthy older adults with long
life expectancy, following the screening
recommendations for all adults with dia-
betes is reasonable. For very old patients
and/or those with multiple comorbidities
and short life expectancy, it is prudent to
weigh the expected beneﬁt time frame of
identifying early signs of complications
and intervening to prevent worsening to
end-stage disease. For the latter group,
particular attention should be paid to
screening for risk factors of complications
that might further impair functional sta-
tus or quality of life over a relatively
short period of time, such as foot ulcers/
amputations and visual impairment.
Considerations in clinical decision mak-
ing should also include prior test results.
For example, there is evidence, including
in the older adult population, that dilated
eye examinations that are initially normal
can safely be repeated every 2–3 years
instead of yearly (55).
What current guidelines exist
for treating diabetes in
older adults?dSeveral organizations
have developed diabetes guidelines speciﬁc
to, or including, older adults. The ADA
includes a section on older adults in its
annual Standards of Medical Care in Di-
abetes (17). The section discusses the het-
erogeneity of persons aged$65 years and
the lack of high-level evidence. The over-
all recommendations, all based on expert
opinion, include the following:
c Older adults who are functional, are
cognitively intact, and have signiﬁcant
life expectancy should receive diabetes
care using goals developed for younger
adults.
c Glycemic goals for older adults not
meeting the above criteria may be re-
laxed using individualized criteria, but
hyperglycemia leading to symptoms or
risk of acute hyperglycemic complica-
tions should be avoided in all patients.
c Other cardiovascular risk factors should
be treated in older adults with consider-
ation of the timeframe of beneﬁt and the
individual patient. Treatment of hyper-
tension is indicated in virtually all older
adults, and lipid and aspirin therapymay
beneﬁt those with life expectancy at least
equal to the timeframe of primary or
secondary prevention trials.
c Screening for diabetes complications
should be individualized in older adults,
but particular attention should be paid
to complications that would lead to
functional impairment.
The ADA goals for glycemic control do
not speciﬁcally mention age. The recom-
mendation for many adults is an A1C
,7%, but less stringent goals are recom-
mended for those with limited life expec-
tancy, advanced diabetes complications, or
extensive comorbid conditions (17).
In collaboration with the ADA and
other medical organizations, the Califor-
nia HealthCare Foundation/American
Geriatrics Society panel published guide-
lines for improving the care of older
adults with diabetes in 2003. A signiﬁcant
proportion of the recommendations con-
cerns geriatric syndromes. Highlights of
diabetes-speciﬁc recommendations in-
clude A1C targets of#7.0% in “relatively
healthy adults,” while for those who are
frail or with life expectancy less than 5
years, a less stringent target, such as 8%,
was considered appropriate. The guide-
lines also suggested that the timeline of
beneﬁts was estimated to be at least 8
years for glycemic control and 2–3 years
for blood pressure and lipid control (2).
The U.S. Department of Veterans Af-
fairs and the U.S. Department of Defense
(VA/DOD) diabetes guidelines were up-
dated in 2010. As with other guidelines,
the VA/DODguidelines do not distinguish
by age-group. They highlight the frequency
of comorbid conditions in patients with
diabetes and stratify glycemic goals based
on comorbidity and life expectancy. For
glycemic goals, for example, the guidelines
have three categories:
c The patientwith either none or verymild
microvascular complications of diabetes,
who is free of major concurrent illnesses
and who has a life expectancy of at least
10–15 years, should have an A1C target
of ,7%, if it can be achieved without
risk.
c The patient with longer-duration di-
abetes (more than 10 years) or with co-
morbid conditions and who requires a
combination medication regimen in-
cluding insulin should have an A1C
target of,8%.
c The patient with advanced microvascu-
lar complications and/or major comorbid
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illness and/or a life expectancy of less
than 5 years is unlikely to beneﬁt from
aggressive glucose-lowering manage-
ment and should have an A1C target of
8–9%. Lower targets (,8%) can be es-
tablished on an individual basis (56).
The European Diabetes Working
Party for Older People recently published
guidelines for treating people with diabe-
tes aged $70 years. These extensive
guidelines recommend that “the decision
to offer treatment should be based on the
likely beneﬁt/risk ratio of the intervention
for the individual concerned, but factors
such as vulnerability to hypoglycemia,
ability to self-manage, the presence or ab-
sence of other pathologies, the cognitive
status, and life expectancy must be con-
sidered” (57). There are recommenda-
tions to carry out annual evaluations of
functional status (global/physical, cogni-
tive, affective) using validated instru-
ments to avoid the use of glyburide due
to its high risk of hypoglycemia in this
population and to calculate cardiovascu-
lar risk in all patients less than 85 years of
age. Suggested A1C targets are based on
age and comorbidity. A range of 7–7.5%
is suggested for older patients with type 2
diabetes withoutmajor comorbidities and
7.6–8.5% for frail patients (dependent,
multisystem disease, home care residency
including those with dementia) where the
hypoglycemia risk may be high and the
likelihood of beneﬁt relatively low.
Extensive review of the guidelines is
beyond the scope of this report, but there
are similar themes, which suggest pursuing
an individualized approach with a focus on
clinical and functional heterogeneity and
comorbidities, and weighing the expected
time frame of beneﬁt of interventions
against life expectancy.
What issues need to be
considered in individualizing
treatment recommendations
for older adults?
Comorbidities and geriatric
syndromes
Diabetes is associated with increased risk
of multiple coexisting medical conditions
in older adults. In addition to the classic
cardiovascular and microvascular diseases,
a group of conditions termed geriatric
syndromes, described below, also occur at
higher frequency in older adults with di-
abetes and may affect self-care abilities and
health outcomes including quality of life
(58).
Cognitive dysfunction. Alzheimer’s-type
and multi-infarct dementia are approxi-
mately twice as likely to occur in those
with diabetes compared with age-matched
nondiabetic control subjects (59). The pre-
sentation of cognitive dysfunction can vary
from subtle executive dysfunction to
overt dementia and memory loss. In the
ACCORD trial, for which referred partici-
pants were felt to be capable of adhering
to a very complex protocol, 20% of those
in the ancillary trial of cognition were
found to have undiagnosed cognitive dys-
function at baseline ( J. Williamson, per-
sonal communication) (60). In this trial,
neither intensive glycemic control nor
blood pressure control to a target SBP
,120 mmHg was shown to prevent a de-
cline in brain function (61). Cross-sectional
studies have shown an association between
hyperglycemia and cognitive dysfunction
(62). Hypoglycemia is linked to cognitive
dysfunction in a bidirectional fashion: cog-
nitive impairment increases the subsequent
risk of hypoglycemia (60), and a history of
severe hypoglycemia is linked to the inci-
dence of dementia (63).
High rates of unidentiﬁed cognitive
deﬁcits in older adults suggest that it is
important to periodically screen for cog-
nitive dysfunction. Simple assessment
tools can be accessed at www.hospitalme-
dicine.org/geriresource/toolbox/howto.
htm. Such dysfunction makes it difﬁcult
for patients to perform complex self-care
tasks such as glucose monitoring, chang-
ing insulin doses, or appropriately main-
taining timing and content of diet. In
older patients with cognitive dysfunction,
regimens should be simpliﬁed, caregivers
involved, and the occurrence of hypogly-
cemia carefully assessed.
Functional impairment. Aging and di-
abetes are both risk factors for functional
impairment. After controlling for age,
people with diabetes are less physically
active and have more functional impair-
ment than those without diabetes (64,65).
The etiology of functional impairment in
diabetes may include interaction between
coexisting medical conditions, peripheral
neuropathy, vision and hearing difﬁculty,
and gait and balance problems. Peripheral
neuropathy, present in 50–70% of older
patients with diabetes, increases the risk
of postural instability, balance problems,
and muscle atrophy (66–68), limiting
physical activity and increasing the risk of
falls. Other medical conditions that com-
monly accompany diabetes such as coro-
nary artery disease, obesity, degenerative
joint disease, stroke, depression, and visual
impairment also negatively impact physical
activity and functionality (69).
Falls and fractures. Normal aging and
diabetes, and the conditionsdescribed above
that impair functionality, are associated with
the higher risk of falls and fractures
(70,71). Women with diabetes have a
higher risk of hip and proximal humeral
fractures after adjustment for age, BMI,
and bone density (71). It is important to
assess fall risks and perform functional as-
sessment periodically in older adults (72).
Avoidance of severe hyperglycemia and
hypoglycemia can decrease the risk of
falls. Physical therapy should be encour-
aged in patients who are at high risk or
who have experienced a recent fall. Medi-
care may cover physical therapy for a lim-
ited time in some of these situations.
Polypharmacy. Older adults with diabe-
tes are at high risk of polypharmacy, in-
creasing the risk of drug side effects and
drug-to-drug interactions. A challenge in
treating type 2 diabetes is that polyphar-
macy may be intentional and necessary to
control related comorbidities and reduce
the risk of diabetes complications (73,74).
In one study, polypharmacy (deﬁned as the
use of six or more prescription medica-
tions) was associated with an increased
risk of falling in older people (75). The
costs of multiple medications can be sub-
stantial, especially when older patients fall
into the “doughnut hole” of Medicare Part
D coverage. Medication reconciliation, on-
going assessment of the indications for each
medication, and the assessment of medica-
tion adherence and barriers are needed at
each visit.
Depression. Diabetes is associated with a
high prevalence of depression (76). Un-
treated depression can lead to difﬁculty
with self-care and with implementing
healthier lifestyle choices (77) and is asso-
ciated with a higher risk of mortality and
dementia in patients with diabetes (78,79).
In older adults, depressionmay remain un-
diagnosed if screening is not performed.
Clinical tools such as the Geriatric Depres-
sion Scale (80) can be used to periodically
screen older patients with diabetes.
Vision and hearing impairment. Sensory
impairments should be considered when
educating older adults and supporting
their self-care. Nearly one in ﬁve older
U.S. adults with diabetes report visual im-
pairment (81). Hearing impairment involv-
ing both high- and low/mid-frequency
sound is about twice as prevalent in people
with diabetes, even after controlling for age
(82) and may be linked to both vascular
disease and neuropathy (83).
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Other commonly occurring medical
conditions. Persistent pain from neuropa-
thy or other causes or its inadequate treat-
ment is associatedwith adverse outcomes in
older adults including functional impair-
ment, falls, slow rehabilitation, depression
and anxiety, decreased socialization, sleep
and appetite disturbances, and higher
health care costs and utilization (2). Pain
should be assessed at every visit in older
patients with the implementation of strate-
gies for amelioration of pain. Urinary incon-
tinence is common in older patients,
especially women, with diabetes. In addi-
tion to standard assessments and treatments
for incontinence, clinicians should remem-
ber that uncontrolled hyperglycemia can
increase the amount and frequency of
urination.
Unique nutrition issues
Nutrition is an integral part of diabetes care
for all ages, but there are additional con-
siderations for older adults with diabetes.
Though energy needs decline with age,
macronutrient needs are similar through-
out adulthood. Meeting micronutrient
needs with lower caloric intake is challeng-
ing; therefore older adults with diabetes are
at higher risk for deﬁciencies. Older adults
may be at risk for undernutrition due to
anorexia, altered taste and smell, swallow-
ing difﬁculties, oral/dental issues, and func-
tional impairments leading to difﬁculties in
preparing or consuming food. Overly re-
strictive eating patterns, either self-imposed
or provider-directed, may contribute ad-
ditional risk for older adults with diabetes.
The Mini-Nutritional Assessment, speciﬁ-
cally designed for older adults, is simple to
perform and may help determine whether
referral to a registered dietitian for medical
nutrition therapy (MNT) is needed (http://
www.mna-elderly.com/).
MNT has proven to be beneﬁcial in
older adults with diabetes (84). Recom-
mendations should take into account
the patient’s culture, preferences, and
personal goals and abilities. When nutri-
tion needs are not being met with usual
intake, additional interventions may in-
clude encouraging smaller more frequent
meals, fortifying usual foods, changing
food texture, or adding liquid nutrition
supplements (either regular or diabetes-
speciﬁc formulas) between meals. For
nutritionally vulnerable older adults, identi-
fying community resources such as Meals
on Wheels, senior centers, and the U.S.
Department of Agriculture’s Older Amer-
icans Nutrition Program may help main-
tain independent living status.
Overweight and obesity are prevalent
among older adults. BMI may not be an ac-
curate predictor of the degree of adiposity
in some older adults due to changes in body
composition with aging (85). Sarcopenia
may occur in both over- and underweight
older adults. Obesity exacerbates decline
in physical function due to aging and
increases the risk of frailty (86). While
unintentional weight loss is a known nu-
trition concern, intentional weight loss in
overweight and obese older adults could
potentially worsen sarcopenia, bone min-
eral density, and nutrition deﬁcits (87,88).
Strategies that combine physical activity
with nutrition therapy to promote weight
loss may result in improved physical per-
formance and function and reduced cardi-
ometabolic risk in older adults (86,87).
Unique needs in diabetes self-
management education/training
and support
Aswithall personswithdiabetes,diabetes self-
management education/training (DSME/T)
for older adults should be individualized
and tailored to the individual’s unique
medical, cultural, and social situation.
Additionally, for older adults, DSME/T
may need to account for possible impair-
ments in sensation (vision, hearing), cog-
nition, and functional/physical status.
Care partnersdfamily, friends, or other
caregiversdshould be involved in DSME/T
to increase the likelihood of successful self-
care behaviors (89). When communicating
with cognitively impaired patients, educa-
tors should address the patient by name
(even when a caregiver will provide most
care), speak in simple terms, use signals
(cues) that aid memory (verbal analogies,
hands-on experience, demonstrations and
models), and utilize strategies such as se-
quenced visits to build on information.
Other tactics include summarizing impor-
tant points frequently, focusing on one
skill at a time, teaching tasks from simple
to complex, and providing easy-to-read
handouts. Even in the absence of cognitive
impairment, educators should consider
that many patients may have low health
literacy and numeracy skills or may be
overwhelmed by the presence of multiple
comorbidities.
Physical activity and ﬁtness
Muscle mass and strength decline with age,
and these decrements may be exacerbated
by diabetes complications, comorbidities,
and periods of hospitalization in older
adults with diabetes. People with diabetes
of longer duration and those with higher
A1Chave lowermuscle strength per unit of
muscle mass than BMI- and age-matched
people without diabetes and than those
whose disease is of shorter duration or
under better glycemic control (90). Al-
though age and diabetes conspire to reduce
ﬁtness and strength, physical activity inter-
ventions improve functional status in older
adults (91) with and without diabetes. In
the Look AHEAD (Action for Health in Di-
abetes) study, participants aged 65–76
years had lower gains in ﬁtness with the
intensive lifestyle intervention than youn-
ger patients, but still improved their mea-
sures of ﬁtness by amean of over 15% (92).
In older adults, even light-intensity physi-
cal activity is associated with higher self-
rated physical health and psychosocial
well-being (93).
Older adults with diabetes who are
otherwise healthy and functional should
be encouraged to exercise to targets rec-
ommended for all adults with diabetes
(17). Even patients with poorer health
status beneﬁt from modest increases in
physical activity. Tactics to facilitate activ-
ity for older adults may include referring
to supervised group exercise and commu-
nity resources such as senior centers,
YMCAs, the EnhanceFitness program, and
the resources of the Arthritis Foundation.
Age-speciﬁc aspects of
pharmacotherapy
Older patients are at increased risk for
adverse drug events from most medica-
tions due to age-related changes in phar-
macokinetics (in particular reduced renal
elimination) and pharmacodynamics (in-
creased sensitivity to certain medications)
affecting drug disposition. These changes
may translate into increased risk for hy-
poglycemia, the potential need for re-
duced doses of certain medications, and
attention to renal function to minimize
side effects (94,95). The risk formedication-
related problems is compounded by the
use of complex regimens, high-cost ther-
apies, and polypharmacy or medication
burden. Collectively, these factors should
be considered and weighed against the
expected beneﬁts of a therapy before in-
corporating it into any therapeutic plan.
Attention to the selection of medications
with a strong beneﬁt-to-risk ratio is essen-
tial to promote efﬁcacy, persistence on
therapy, and safety.
Antihyperglycemic medication use in
older adults. Comparative effectiveness
studies of medications to treat diabetes in
older adult populations are lacking. Type
2 diabetes with onset later in life is
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characterized by prominent defects in
b-cell function, suggesting therapeutic at-
tention to b-cell function and sufﬁciency
of insulin release, as well as the traditional
focus on hepatic glucose overproduction
and insulin resistance. Understanding the
advantages and disadvantages of each an-
tihyperglycemic drug class helps clini-
cians individualize therapy for patients
with type 2 diabetes (96). Issues particu-
larly relevant to older patients are de-
scribed for each drug class.
Metformin is often considered the
ﬁrst-line therapy in type 2 diabetes. Its
low risk for hypoglycemia may be bene-
ﬁcial in older adults, but gastrointestinal
intolerance and weight loss from the drug
may be detrimental in frail patients. De-
spite early concerns, the evidence for an
increase in the risk of lactic acidosis with
metformin is minimal. The dose should
be reduced if estimated glomerular ﬁltra-
tion rate (eGFR) is 30–60 mL/min, and
the drug should not be used if eGFR is
,30 mL/min (94,97). Metformin’s low
cost may be a beneﬁt in those on multiple
medications or who are subject to the
Medicare Part D “doughnut hole.”
Sulfonylureas are also a low-cost class
of medications, but the risk of hypoglyce-
mia with these agents may be problematic
for older patients. Glyburide has the highest
hypoglycemia risk and should not be pre-
scribed for older adults (98). Glinides are
dosed prior to meals, and their short
half-life may be useful for postprandial hy-
perglycemia. They impart a lower risk for
hypoglycemia than sulfonylureas, especially
inpatientswho eat irregularly, but their dos-
ing frequency andhigh costmaybebarriers.
a-Glucosidase inhibitors speciﬁcally
target postprandial hyperglycemia and
have low hypoglycemia risk, making
them theoretically attractive for older pa-
tients. However, gastrointestinal intoler-
ance may be limiting, frequent dosing adds
to regimen complexity, and this class of
medications is costly. Thiazolidinediones
have associated risks of weight gain,
edema, heart failure, bone fractures, and
possibly bladder cancer, which may argue
against their use in older adults. The use
of rosiglitazone is now highly restricted.
The class has traditionally been expen-
sive, although the approval of generic
pioglitazone may reduce its cost.
Dipeptidyl peptidase-4 inhibitors are
useful for postprandial hyperglycemia, im-
part little risk for hypoglycemia, and are
well tolerated, suggesting potential beneﬁts
for older patients. However, their high cost
may be limiting. Glucagon-like peptide-1
agonists also target postprandial hypergly-
cemia and impart low risk of hypoglyce-
mia, but their associated nausea andweight
loss may be problematic in frail older
patients. Injection therapy may add to re-
gimen complexity, and its very high cost
may be problematic. For some agents, dose
reduction is required for renal dysfunction.
Insulin therapy can be used to achieve
glycemic goals in selected older adults
with type 2 diabetes with similar efﬁcacy
and hypoglycemia risk as in younger
patients. However, given the heterogene-
ity of the older adult population, the risk
of hypoglycemia must be carefully con-
sidered before using an insulin regimen to
achieve an aggressive target for hypergly-
cemia control. A mean A1C of 7% was
achieved and maintained for 12 months
with either an insulin pump regimen or
multiple daily insulin injections in other-
wise healthy and functional older adults
(mean age 66 years), with low rates of
hypoglycemia (99). The addition of long-
acting insulin was similarly effective in
achieving A1C goals for older patients
with type 2 diabetes (mean age 69 years)
in a series of trials with no greater rates of
hypoglycemia than in younger patients
(mean age 53 years) (100). However,
there are few data on such regimens in
people over age 75 years or in older adults
with multiple comorbidities and/or lim-
ited functional status who were excluded
from these trials.
Problems with vision or manual dex-
terity may be barriers to insulin therapy
for some older adults. Pen devices im-
prove ease of use but are more costly than
the use of vials and syringes. Hypoglycemia
risk (especially nocturnal) is somewhat lower
with analog compared with human insulins,
but the former are more expensive. Insulin-
induced weight gain is a concern for some
patients, and theneed formorebloodglucose
monitoring may increase treatment burden.
Other approved therapies for which
there is little evidence in older patients
include colesevelam, bromocriptine, and
pramlintide. An emerging drug class,
sodium-glucose cotransporter-2 inhibi-
tors, may require additional study in older
adults to assess whether drug-associated
genital infections or urinary incontinence
is problematic in this population.
Vulnerability to hypoglycemia. Age ap-
pears to affect counter-regulatory respon-
ses to hypoglycemia in nondiabetic
individuals. During hypoglycemic clamp
studies, symptoms begin at higher glu-
cose levels and have greater intensity in
younger men (aged 22–26 years), while
measures of psychomotor coordination
deteriorate earlier and to a greater degree
in the older subjects (aged 60–70 years),
erasing the usual 10–20 mg/dL plasma
glucose difference between subjective
awareness of hypoglycemia and onset of
cognitive dysfunction (101). Studies in
older individuals with diabetes are limited.
One small study compared responses to hy-
poglycemic clamps in older (mean age 70
years) versus middle-aged (mean age 51
years) people with type 2 diabetes. Hor-
monal counter-regulatory responses to
hypoglycemia did not differ between age-
groups, but middle-aged participants had
a signiﬁcant increase in autonomic and neu-
roglycopenic symptoms at the end of the
hypoglycemic period, while older parti-
cipants did not. Half of the middle-aged
participants, but only 1 out of 13 older par-
ticipants, correctly reported that their blood
glucosewas lowduringhypoglycemia (102).
The prevalence of any hypoglycemia
(measured blood glucose below70mg/dL)
or severe hypoglycemia (requiring third-
party assistance) in older populations is
not known. In the ACCORD trial, older
participants in both glycemic intervention
arms had;50% higher rates of severe hy-
poglycemia (hypoglycemia requiring third-
party assistance) than participants under
age 65 years (M. Miller, personal commu-
nication). In a population analysis of Med-
icaid enrollees treated with insulin or
sulfonylureas, the incidence of serious hy-
poglycemia (deﬁned as that leading to
emergency department visit, hospitaliza-
tion, or death) was approximately 2 per
100 person-years (103), but clearly studies
based on administrative databasesmiss less
catastrophic hypoglycemia.
The risk factors for hypoglycemia in
diabetes in general (use of insulin or insulin
secretagogues, duration of diabetes, ante-
cedent hypoglycemia, erratic meals, exer-
cise, renal insufﬁciency) (104) presumably
apply to older patients as well. In the Med-
icaid study cited above, independent risk
factors included hospital discharge within
the prior 30 days, advanced age, black race,
and use of ﬁve or more concomitant med-
ications (103). Assessment of risk factors for
hypoglycemia is an important part of the
clinical care of older adults with hypoglyce-
mia. Education of both patient and care-
giver on the prevention, detection, and
treatment of hypoglycemia is paramount.
Risks of undertreatment of hypergly-
cemia. Although attention has rightly
been paid to the risks of overtreatment
of hyperglycemia in older adults (hypogly-
cemia, treatment burden, possibly increased
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mortality), untreated or undertreated hy-
perglycemia also has risks, even in patients
with life expectancy too short to be im-
pacted by the development of chronic
complications. Blood glucose levels consis-
tently over the renal threshold for glycos-
uria (;180–200 mg/dL, but can vary)
increase the risks for dehydration, electro-
lyte abnormalities, urinary incontinence,
dizziness, and falls. Hyperglycemic hyper-
osmolar syndrome is a particularly severe
complication of unrecognized or under-
treated hyperglycemia in older adults. Al-
though it is appropriate to relax glycemic
targets for older patients with a history of
hypoglycemia, a high burden of comorbid-
ities, and limited life expectancy, goals that
minimize severe hyperglycemia are indi-
cated for almost all patients.
Life expectancy
A central concept in geriatric diabetes
care guidelines is that providers should
base decisions regarding treatment targets
or interventions on life expectancy
(2,17,56,57). Patients whose life expec-
tancy is limited (e.g., ,5 years, ,10
years) are considered unlikely to beneﬁt
from intensive glucose control, for ex-
ample, whereas those with longer life ex-
pectancy may be appropriate candidates
for this intervention. An observation sup-
porting this concept is that cumulative
event curves for the intensive and conven-
tional glycemic control arms of the
UKPDS separated after the 9-year mark.
National Vital Statistics life table esti-
mates of average life expectancy for adults
of speciﬁc ages, sexes, and races (105)
may not apply to older adults with diabe-
tes, who have shorter life expectancies
than the average older adult. Mortality
prediction models that account for varia-
bles such as comorbidities and functional
status can serve as the basis for making
more reﬁned life expectancy estimates
(106–108). Mortality prediction models
speciﬁc to diabetes exist but were not
designed to inform treatment decisions
(109,110). A limitation of existing mor-
tality models is that they can help to rank
patients by probability of death, but these
probabilities must still be transformed
into a life expectancy for a particular older
diabetic patient.
Simulation models can help trans-
form mortality prediction into a usable
life expectancy. One such model esti-
mated the beneﬁts of lowering A1C
from 8.0 to 7.0% for hypothetical older
diabetic patients with varying levels of
age, comorbidity, and functional status
(111). A combination of multiple comor-
bid illnesses and functional impairments
was a better predictor of limited life ex-
pectancy and diminished beneﬁts of in-
tensive glucose control than age alone.
This model suggests that life expectancy
averages less than 5 years for patients aged
60–64 years with seven additional index
points (points due to comorbid conditions
and functional impairments), aged 65–69
Table 1dA framework for considering treatment goals for glycemia, blood pressure, and dyslipidemia in older adults with diabetes
Patient characteristics/
health status Rationale
Reasonable A1C goal
(A lower goal may be
set for an individual if
achievable without
recurrent or severe
hypoglycemia or undue
treatment burden)
Fasting or
preprandial
glucose (mg/dL)
Bedtime
glucose
(mg/dL)
Blood
pressure
(mmHg) Lipids
Healthy
(Few coexisting chronic
illnesses, intact cognitive
and functional status)
Longer remaining life
expectancy
,7.5% 90–130 90–150 ,140/80 Statin unless
contraindicated
or not tolerated
Complex/intermediate
(Multiple coexisting
chronic illnesses*
or 21 instrumental ADL
impairments or mild to
moderate cognitive
impairment)
Intermediate remaining
life expectancy, high
treatment burden,
hypoglycemia
vulnerability, fall risk
,8.0% 90–150 100–180 ,140/80 Statin unless
contraindicated
or not tolerated
Very complex/poor health
(Long-term care or
end-stage chronic illnesses**
or moderate to severe
cognitive impairment
or 21 ADL dependencies)
Limited remaining life
expectancy makes
beneﬁt uncertain
,8.5%† 100–180 110–200 ,150/90 Consider likelihood
of beneﬁt with
statin (secondary
prevention moreso
than primary)
This represents a consensus framework for considering treatment goals for glycemia, blood pressure, and dyslipidemia in older adults with diabetes. The patient
characteristic categories are general concepts. Not every patient will clearly fall into a particular category. Consideration of patient/caregiver preferences is an im-
portant aspect of treatment individualization. Additionally, a patient’s health status and preferences may change over time. ADL, activities of daily living. *Coexisting
chronic illnesses are conditions serious enough to require medications or lifestyle management andmay include arthritis, cancer, congestive heart failure, depression,
emphysema, falls, hypertension, incontinence, stage III or worse chronic kidney disease, MI, and stroke. By multiple we mean at least three, but many patients may
have ﬁve or more (132). **The presence of a single end-stage chronic illness such as stage III–IV congestive heart failure or oxygen-dependent lung disease, chronic
kidney disease requiring dialysis, or uncontrolled metastatic cancer may cause signiﬁcant symptoms or impairment of functional status and signiﬁcantly reduce life
expectancy. †A1C of 8.5% equates to an estimated average glucose of ;200 mg/dL. Looser glycemic targets than this may expose patients to acute risks from
glycosuria, dehydration, hyperglycemic hyperosmolar syndrome, and poor wound healing.
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yearswith six additional points, aged70–74
years with ﬁve additional points, and aged
75–79 years with four additional points. An
example of comorbid illnesses is the diag-
nosis of cancer, which confers two points,
whereas an example of a functional impair-
ment is the inability to bathe oneself, con-
ferring two points.
Shared decision making
In light of the paucity of data for diabetes
care in older adults, treatment decisions
are frequently made with considerable
uncertainty. Shared decision making has
been advocated as an approach to improv-
ing the quality of these so-called preference-
sensitive medical decisions (112,113). Key
components of the shared decision-making
approach are 1) establishing an ongoing
partnership between patient and provider,
2) information exchange, 3) deliberation on
choices, and 4) deciding and acting on de-
cisions (114).
When asked about their health care
goals, older diabetic patients focus most on
their functional status and independence
(115). A key component of improving
communication in the clinical setting may
be ﬁnding congruence between patient
goals and the biomedical goals on which
clinicians tend to focus. Discussions elicit-
ing and incorporating patients’ preferences
regarding treatments and treatment targets
may be difﬁcult when patients do not un-
derstand the signiﬁcance of risk factors or
the value of risk reduction. Thus, providers
must ﬁrst educate patients and their care-
givers about what is known about the role
of risk factors in the development of com-
plications and then discuss the possible
harms and beneﬁts of interventions to re-
duce these risk factors.
Equally important is discussing the
actual medications that may be needed to
achieve treatment goals because patients
may have strong preferences about the
treatment regimen. In a study of patient
preferences regarding diabetes complica-
tions and treatments, end-stage complica-
tions had the greatest perceived burden on
quality of life; however, comprehensive
diabetes treatments had signiﬁcant negative
perceived quality-of-life effects, similar to
those of intermediate complications (116).
Preferences for each health state varied
widely among patients, and this variation
was not related to health status (117), im-
plying that the preferences of an individual
patient cannot be assumed to be known
based on health status.
Many older adults rely on family
members or friends to help them with
their treatment decisions or to implement
day-to-day treatments. In the case of the
older person with cognitive deﬁcits, the
family member or friend may in fact be
serving as a surrogate decisionmaker. Prior
studies of older cognitively intact patients
have shown that surrogate decisionmakers
often report treatment preferences for the
patient that have little correlation with the
patient’s views (118), highlighting the im-
portance of eliciting patient preferences
whenever possible.
Racial and ethnic disparities
Among older adults, African Americans
and Hispanics have higher incidence and
prevalence of type 2 diabetes than non-
Hispanic whites, and those with diagnosed
diabetes have worse glycemic control and
higher rates of comorbid conditions and
complications (119). The Institute of
Medicine found that although health care
access and demographic variables account
for some racial and ethnic disparities,
there are persistent, residual gaps in
Table 2dAdditional consensus recommendations for care of older adults with diabetes
Screening for and prevention of diabetes
Screen older adults for prediabetes and diabetes according to ADA recommendations, if the patient will be likely to beneﬁt from identiﬁcation of
the condition/disease and subsequent intervention.
Implement lifestyle intervention for older adults with prediabetes who are able to participate and are likely to beneﬁt from the prevention of type
2 diabetes.
Management of diabetes
Encourage physical activity, even if not to optimal levels, and implement MNT using simple teaching strategies and community resources while
considering patient safety and preferences.
DSME/T in older adults should take into account sensory deﬁcits, cognitive impairment, and different learning styles and teaching strategies and
should include caregivers.
In order to develop and update an individualized treatment plan, screen older adults periodically for cognitive dysfunction, functional status, and
fall risk, using simple tools such as those at http://www.hospitalmedicine.org/geriresource/toolbox/determine.htm.
Pharmacotherapy
Carefully choose antihyperglycemic therapies, considering polypharmacy. Avoid glyburide in older adult patients. Metformin can be used safely
and is the preferred initial therapy in many older adults with type 2 diabetes, but at reduced dose in those with stage III chronic kidney disease,
and avoid in those with stage IV or worse. Assess renal function using eGFR, not serum creatinine alone.
Assess patients for hypoglycemia regularly by asking the patient and caregiver about symptoms or signs and reviewing blood glucose logs. In type
2 diabetic patients, hypoglycemia risk is linked more to treatment strategies than to achieved lower A1C (e.g., a patient with a low A1C on
metformin alone may be at considerably lower risk of hypoglycemia than a patient with a high A1C on insulin).
If recurrent or severe hypoglycemia occurs, strongly consider changing therapy and/or targets.
Assess the burden of treatment on older adult patients (caregivers), consider patient/caregiver preferences, and attempt to reduce treatment
complexity.
Management of older adults with diabetes in settings outside the home
The glycemic goals for hospitalized older adults with diabetes are usually similar to those for the general population. The use of SSI alone for
chronic glycemic management is discouraged in inpatient settings as well as in LTC facilities.
Transitions of older adults with diabetes (e.g., from home or LTC facility to hospital to postdischarge setting) are periods of high risk. Careful
medication reconciliation and written information regarding medication dosing and timing help to minimize risk for hyper- and
hypoglycemia. Early transition of diabetes care to an outpatient provider is important to modify drug therapy according to changes in
clinical status.
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outcomes attributed to differences in the
quality of care received (120). There is
clearly a need for more research into the
disparities in diabetes, particularly to
understand the full impact of quality im-
provement programs and culturally tai-
lored interventions among vulnerable
older adults with diabetes.
Settings outside the home
Long-term care facilities. Long-term care
(LTC) facilities include nursing homes,
whichprovide 24-hnursing care for patients
in either residential care or rehabilitative
care, and adult family homeswhere the level
of care is not as acute. Diabetes is common
in LTC facilities, with an overall diabetes
prevalence of 25% (22% in Caucasian and
36% in non-Caucasian residents) (121).
LTC residents with diabetes have more falls
(122), higher rates of CVD and depression,
more functional impairment, and more
cognitive decline and dependency than
residents without diabetes (123).
The LTC facility resident may have
irregular and unpredictable meal con-
sumption, undernutrition, anorexia, and
impaired swallowing. Therapeutic diets
may inadvertently lead to decreased food
intake and contribute to unintentional
weight loss and undernutrition. Serving
meals that take into account the patient’s
culture, preferences, personal goals, and
abilities may increase quality of life, satis-
faction with meals, and nutrition status
(124). Vulnerable older adults, particu-
larly those with cognitive dysfunction,
may have impaired thirst sensation,
contributing to the risk of volume deple-
tion and hyperglycemic crises. Precipitat-
ing situations include illness, institutional
settings (LTC or hospital), aversion to
drinking water, dysphasia requiring
thickened liquids, and some medications
(125). Fluid intake should be encouraged
and monitored in an institutional setting.
A major issue in LTC facilities is fre-
quent staff turnover with resultant unfa-
miliarity with vulnerable residents (126).
There is often inadequate oversight of gly-
cemic control related to infrequent review
of glycemic trends, complex and difﬁcult-
to-read glucose logs, and lack of speciﬁc
diabetes treatment algorithms including
glycemic parameters for provider notiﬁca-
tion (127). Excessive reliance on sliding-
scale insulin (SSI) has been documented.
Table 3dConsensus recommendations for research questions about diabetes in older adults
c What speciﬁc cellular and molecular mechanisms deﬁne the interactions between aging and lifestyle factors that underlie the high rates of
diabetes in the older adult population? How can such mechanisms be used to develop effective intervention strategies?
c How does aging affect the trajectories of development of macro- and microvascular complications over time?
c What are the best interventions to prevent type 2 diabetes in older adults? How can evidence-based lifestyle intervention strategies be widely
implemented in the community in ways that maximize the participation of older adults?
c More studies of the mechanisms of the link between diabetes and cognitive impairment should be conducted. Many diabetes trials that include
older adults should include the assessment of cognition as a covariate or outcome. Does treatment of hyperglycemia in general or via particular
strategies reduce the risk of diabetes-associated cognitive impairment? Is such cognitive impairment slowed or prevented by diabetes prevention
strategies?
c What is the optimal level of blood pressure control in older adults with diabetes? What are the best treatment strategies?
c Do speciﬁc diabetes interventions prevent or slow decline in functional status in older adults?
c How can fall risk be reduced in older adults with diabetes?
c Can we make it easier for clinicians to anticipate the expected lifetime beneﬁts of interventions, such as decision support tools for life expectancy
embedded in electronic health records? What impact will formal use of prognostic information have on diabetes care and patient outcomes?
c What aspects of patient-provider communication are most effective in shared decision making with older patients and caregivers?
c What are the ethical and patient preference concerns about de-intensifying therapy in older adults who are deemed unlikely to reap beneﬁts from
aggressive therapy of diabetes and its comorbidities?
c Comparative effectiveness studies of diabetes therapies in older adults should be undertaken. Does comparative effectiveness differ for older
compared with younger adults?
c What are the health literacy/numeracy issues in this population, and how can they best be addressed?
c What is the true incidence of hypoglycemia in older adults? How can it be recognized and reduced?What are themechanisms of the bidirectional
association of severe hypoglycemia with cognitive impairment? Is the relationship of hypoglycemia to cardiovascular outcomes a direct cause/
effect, or is it more complex?
c What is the impact of geriatric syndromes on the management of diabetes and on the risk for adverse treatment effects and poor outcomes?
c What are signiﬁcant race/ethnic disparities among older adults with diabetes, and what are the best approaches to addressing them?
c What strategies are effective for increasing physical activity in older adults with diabetes? What are the effects of exercise on clinical and
psychosocial outcomes?
c Is there evidence that intentional weight loss is beneﬁcial in overweight older adults with diabetes?
c What are the best strategies for DSME/S in older adults? What are the roles of technology, group versus individual education, and support by
community resources?
c What are the unique stressors of caregivers of these older adults with diabetes, and how can they be addressed?
c What are the mechanisms of the impact of diabetes and speciﬁc therapies on bone health?
c What is the expected time frame of beneﬁt of diabetes interventions, including complications screening and care? Such studies will likely require
the use of longitudinal studies and registries rather than randomized controlled trials.
c What is the appropriate frequency and cost-effectiveness of self-monitored blood glucose in heterogeneous older adults with diabetes?
c Studies of older patients in hospitals and LTC facilities are greatly needed. What are appropriate treatment goals and strategies for these
populations? How can transitions of care (e.g., between hospital and LTC facility) be optimized to maximize patient safety?Will system changes,
such as accountable care organizations, improve outcomes in vulnerable older adults?
DSME/S, diabetes self-management education/support.
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One study showed that 83% of residents
started on SSI were still treated by SSI alone
6 months later (128). Evidence-based pol-
icies for glycemic control, use of insulin,
and treatment of hypoglycemia have the
potential to improve the care of residents
with diabetes, alleviate some of the burden
caused by frequent staff turnover, and even
lead to more staff satisfaction.
Hospitals. Older adults are more apt to
require hospitalization than younger adults,
and those with diabetes are at very high risk
of requiring hospitalization. There is a
dearth of studies addressing older adults
with diabetes, particularly more frail older
adults, in the hospital. Many guidelines that
apply to hospitalized adults with hypergly-
cemia can probably be extrapolated to older
adults (129,130). Current guidelines rec-
ommend preprandial glycemic targets of
100–140 mg/dL with maximal random
values of 180mg/dL in the majority of non-
critically ill hospitalized patients, provided
these targets can be safely achievedwith low
risk for hypoglycemia. Less stringent glyce-
mic targets may be appropriate for patients
with multiple comorbidities and reduced
life expectancydcriteria that could be ap-
plicable to many hospitalized older adults.
However, in general, glucose levels should
be maintained at values below 200 mg/dL
to minimize symptomatic hyperglycemia
with associated ﬂuid and electrolyte ab-
normalities, renal complications, and risk
for infection (129,130). Studies of glyce-
mic control targets in critically ill patients
did include older adults, and therefore
the recommendations for insulin infu-
sions and glycemic goals of the ADA
(17) are reasonable for older adults in in-
tensive care units. Other recommenda-
tions for all adults, such as avoiding the
use of sliding scale–only regimens and
noninsulin antihyperglycemic drugs, are
also reasonable for hospitalized older
adults.
Transitions from hospital to home or
to short- or long-term care facilities are
times of risk for patients with diabetes,
and probably more so for older patients.
Older patients on insulin may need to
increase or decrease their dose as they
recuperate from their acute illness and
their diet improves. Delirium (acute de-
cline in cognitive function) is a common
complication seen in older adults dur-
ing and after hospitalization and may
require more supervision to avoid errors
in dosing. Medication reconciliation, pa-
tient and caregiver education, and close
communication between inpatient and
outpatient care teams, are critically im-
portant to ensure patient safety and re-
duce readmission rates.
What are consensus
recommendations for clinicians
treating older adults with or at
risk for diabetes?dAlthough sev-
eral organizations have developed guide-
lines that pertain to older adults and/or
those with signiﬁcant comorbidity, lack
of evidence makes it somewhat difﬁcult to
provide concrete guidance for clinicians.
After review of the available evidence and
consideration of issues that might inﬂu-
ence treatment decisions in older adults
with diabetes, the authors have developed
recommendations in a number of areas.
Table 1 provides a framework for consid-
ering treatment goals for glycemia, blood
pressure, and dyslipidemia. This frame-
work is based on the work of Blaum
et al. (131), in which health status, de-
ﬁned by the presence and number of co-
morbidities or impairments of functional
status, leads to the identiﬁcation of three
major classes of older patients: 1) those
who are relatively healthy, 2) those with
complex medical histories where self-care
may be difﬁcult, and 3) those with a very
signiﬁcant comorbid illness and func-
tional impairment. The three classes cor-
respond with increasing levels of
mortality risk (131). The observation
that there are three major classes of older
diabetic patients is supported by other re-
search (132). The framework is an at-
tempt to balance the expected time
frame of beneﬁt of interventions with an-
ticipated life expectancy. Table 2 provides
additional consensus recommendations
beyond goals of treatment of glycemia,
blood pressure, and dyslipidemia.
How can gaps in the
evidence best be ﬁlled?dThe
exclusion of older, and especially frail
older, participants from most traditional
randomized controlled trials of diabetes
interventions has left us with large gaps in
our knowledge of how best to address
diabetes in the age-group with the highest
prevalence rates. Future research should
allow and account for the complexity and
heterogeneity of older adults. Studies will
need to include patients with multiple
comorbidities, dependent living situations,
and geriatric syndromes in order to advance
our knowledge about these populations.
Beyond broadening the inclusion criteria
for randomized controlled trials, we will
increasingly need sophisticated observa-
tional or comparative effectiveness evi-
dence from “real world” settings and
populations. Suggested research ques-
tions and topics are listed in Table 3.
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